UB Paderborn / Katalog / Suche / in CDI

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Nature communications, 2020-11, Vol.11 (1), p.5824-15, Article 5824

2020

Link zum Volltext

Verfügbarkeit prüfen

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Breast cancer research and treatment, 2022-02, Vol.191 (3), p.565-576

2022

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Clinical breast cancer, 2019-02, Vol.19 (1), p.1-9

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5270-5277

2009

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

The lancet oncology, 2020-10, Vol.21 (10), p.1283-1295

2020

Link zum Volltext

Verfügbarkeit prüfen

Apoptosis of multiple myeloma

International journal of hematology, 2004-10, Vol.80 (3), p.224-231

2004

Link zum Volltext

Verfügbarkeit prüfen

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Breast cancer research and treatment, 2021-09, Vol.189 (2), p.377-386

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS5-06-PS5-06

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-04-GS3-04

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-03-PD14-03

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1037-1037

2018

Link zum Volltext

Verfügbarkeit prüfen

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.617-624

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-23

2020

Link zum Volltext

Verfügbarkeit prüfen

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS1117-TPS1117

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT049-CT049

2019

Link zum Volltext

Verfügbarkeit prüfen

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

The Journal of immunology (1950), 2011-03, Vol.186 (6), p.3401-3409

2011

Link zum Volltext

Verfügbarkeit prüfen

Chlorophosphonates: Inexpensive Precursors for Stereodefined Chloro-Substituted Olefins and Unsymmetrical Disubstituted Acetylenes

Journal of organic chemistry, 2000-06, Vol.65 (12), p.3733-3737

2000

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets

Journal of Immunology, 2006-07, Vol.177 (1), p.120-129

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-11-08: Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P3-P3-11-08

2015

Link zum Volltext

Verfügbarkeit prüfen

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.7-14

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1048-1048

2015

Link zum Volltext

Verfügbarkeit prüfen

phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Breast cancer research and treatment, 2009-09, Vol.117 (1), p.83-89

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2686: Anti-tumor effects of a folate-immunoglobulin conjugate are enhanced by cytokine treatment in vitro and in vivo

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2686-2686

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer

Breast cancer research and treatment, 2009-09, Vol.117 (1), p.83

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Apoptosis of multiple myeloma

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC)

Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

Chlorophosphonates: Inexpensive Precursors for Stereodefined Chloro-Substituted Olefins and Unsymmetrical Disubstituted Acetylenes

Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets

Abstract P3-11-08: Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC)

phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Abstract 2686: Anti-tumor effects of a folate-immunoglobulin conjugate are enhanced by cytokine treatment in vitro and in vivo

NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer

Aktive Filter

Suchergebnisse filtern